Cytotoxic Tumor-Infiltrating Lymphocytes in Metastatic HER2-Positive Breast Cancer

This secondary analysis of a phase 3 randomized clinical trial investigates the role of tumor-infiltrating lymphocytes in predicting outcomes in patients with HER2-positive metastatic breast cancer randomized to antibody vs small molecule–based anti-HER2 therapy.

from Cancer via ola Kala on Inoreader http://ift.tt/2yn5Cun
via IFTTT